This is a multicenter, non-interventional and observational real-world study to evaluate the efficacy and safety of linperlisib in patients with lymphoma.
Study Type
OBSERVATIONAL
Enrollment
1,000
80 mg, qd
Ruijin Hospital, Shanghai Jiao Tong University School of Medicine
Shanghai, China
Tianjin Cancer Hospital/ Tianjin medical university cancer institute & hospital
Tianjin, China
Rate of adverse events (AEs)/ serious adverse events (SAEs)
Rate of adverse events (AEs)/ serious adverse events (SAEs) in patients with lymphoma receiving linperlisib therapy
Time frame: up to 4 weeks after the last dose
Complete response rate
Percentage of participants with complete response was determined on the basis of investigator assessments according to 2014 Lugano criteria.
Time frame: 6 months
Progression-free survival
Progression-free survival was defined as the time from the date of enrollment until the date of the first documented day of disease progression or relapse, using 2014 Lugano criteria, or death from any cause, whichever occurred first.
Time frame: 1 years and 2 years
Overall survival
Overall survival was defined as the time from the date of enrollment to the date of death from any cause.
Time frame: Baseline up to data cut-off (up to approximately 2 years)
Duration of response
Duration of response was defined as the time from the date of favorable response until the date of the first documented day of disease progression or relapse, using 2014 Lugano criteria
Time frame: Baseline up to data cut-off (up to approximately 2 years)
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.